Exact Mass: 392.2423432
Exact Mass Matches: 392.2423432
Found 500 metabolites which its exact mass value is equals to given mass value 392.2423432,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Kalihinol A
C22H33ClN2O2 (392.22304280000003)
Trospium
C25H30NO3+ (392.22255700000005)
Trospium is only found in individuals that have used or taken this drug. It is a urinary antispasmodic. It is sold under the brand name Sanctura in the US, and as Trosec in Canada. [Wikipedia]Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.
3-Hydroxy-10'-apo-b,y-carotenal
3-Hydroxy-10-apo-b,y-carotenal is found in citrus. 3-Hydroxy-10-apo-b,y-carotenal isisolated from Sinton citrangequat. Prob. isolated from Sinton citrangequat. 3-Hydroxy-10-apo-b,y-carotenal is found in citrus.
Dihydrofukinolide
Dihydrofukinolide is found in giant butterbur. Dihydrofukinolide is a constituent of Petasites japonicus (sweet coltsfoot) Constituent of Petasites japonicus (sweet coltsfoot). Dihydrofukinolide is found in giant butterbur and green vegetables.
Methyl (9Z)-6'-oxo-6,5'-diapo-6-carotenoate
Methyl (9Z)-6-oxo-6,5-diapo-6-carotenoate is a constituent of Bixa orellana (annatto) Constituent of Bixa orellana (annatto).
CPA(16:0/0:0)
cPA(16:0/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(16:0/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.
Indacaterol
C24H28N2O3 (392.20998180000004)
Indacaterol is a novel, ultra-long-acting, (2)-adrenoceptor agonist developed for Novartis for the once-daily treatment of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. Indacaterol is provided as a pure R-enantiomer, typically as the salt indacaterol maleate. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research[1][2].
Ivacaftor
C24H28N2O3 (392.20998180000004)
Ivacaftor is only found in individuals that have used or taken this drug. It is a drug for the treatment of cystic fibrosis, developed by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation.Cystic fibrosis is caused by any one of several defects in a protein, cystic fibrosis transmembrane conductance regulator, which regulates fluid flow within cells and affects the components of sweat, digestive fluids, and mucus. The defect, which is caused by a mutation in the individuals DNA, can be in any of several locations along the protein, each of which interferes with a different function of the protein. One mutation, G551D, lets the CFTR protein reach the epithelial cell surface, but doesnt let it transport chloride through the ion channel. Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the G551D-CFTR protein. D049990 - Membrane Transport Modulators > D065101 - Chloride Channel Agonists C87006 - Pharmacological Chaperone R - Respiratory system
20, 22-Dihydrodigoxigenin
20, 22-Dihydrodigoxigenin is a metabolite of digoxin. Digoxin is a purified cardiac glycoside and extracted from the foxglove plant, Digitalis lanata. Its corresponding aglycone is digoxigenin, and its acetyl derivative is acetyldigoxin. Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade names Lanoxin, Digitek, and Lanoxicaps. (Wikipedia)
10-Hydroperoxy-H4-neuroprostane
10-Hydroperoxy-H4-neuroprostane, also known as 10-H4-NeuroP, is a member of the class of compounds known as prostaglandins and related compounds. Prostaglandins and related compounds are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five-member ring, and are based upon the fatty acid arachidonic acid. 10-Hydroperoxy-H4-neuroprostane is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Within the cell, 10-hydroperoxy-H4-neuroprostane is primarily located in the membrane (predicted from logP). It can also be found in the extracellular space.
11-Hydroperoxy-H4-neuroprostane
11-Hydroperoxy-H4-neuroprostane, also known as 11-H4-NeuroP, is a member of the class of compounds known as prostaglandins and related compounds. Prostaglandins and related compounds are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five-member ring, and are based upon the fatty acid arachidonic acid. 11-Hydroperoxy-H4-neuroprostane is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Within the cell, 11-hydroperoxy-H4-neuroprostane is primarily located in the membrane (predicted from logP). It can also be found in the extracellular space.
14-Hydroperoxy-H4-neuroprostane
14-Hydroperoxy-H4-neuroprostane, also known as 14-H4-NeuroP, is a member of the class of compounds known as prostaglandins and related compounds. Prostaglandins and related compounds are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five-member ring, and are based upon the fatty acid arachidonic acid. 14-Hydroperoxy-H4-neuroprostane is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Within the cell, 14-hydroperoxy-H4-neuroprostane is primarily located in the membrane (predicted from logP). It can also be found in the extracellular space.
(R)-5-(2-(5,6-Diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
C24H28N2O3 (392.20998180000004)
Arterolane
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
Dextromoramide
C25H32N2O2 (392.24636519999996)
Glycylphenylalanylleucylglycine
N,N'-Dibenzhydrylethane-1,2-diamine
AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects[1][2].
Naftopidil
C24H28N2O3 (392.20998180000004)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].
N'-[(6-Oxo-5-prop-2-enyl-1-cyclohexa-2,4-dienylidene)methyl]-2-[4-(phenylmethyl)-1-piperazinyl]acetohydrazide
VIPROSTOL
MG(20:4(6E,8Z,11Z,14Z)+=O(5)/0:0/0:0)
MG(20:4(6E,8Z,11Z,14Z)+=O(5)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:4(5Z,8Z,11Z,13E)+=O(15)/0:0/0:0)
MG(20:4(5Z,8Z,11Z,13E)+=O(15)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0/0:0)
MG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0/0:0)
MG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0/0:0)
MG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0/0:0)
MG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0)
MG(0:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0)
MG(0:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0)
MG(0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0)
MG(0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0)
MG(0:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0)
MG(0:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
Blinin
Blinin is a natural product found in Eschenbachia blinii with data available. Blinin is a neoclerodane diterpene, isolated from the whole plant of Conyza blinii[1]. Blinin is a neoclerodane diterpene, isolated from the whole plant of Conyza blinii[1].
4beta,8beta,2alpha-Trihydroxy-6alpha-p-hydroxybenzoyloxydaucane
6alpha-Malonyloxymanoyl oxide
The malonate ester of a labdane diterpenoid. Isolated from the aerial parts of Stemodia foliosa, it exhibits antibacterial activity.
naftopidil
C24H28N2O3 (392.20998180000004)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].
(1SR,3SR,5SR,8RS,11RS,12S)-3-hydroxy-8,12-dimethyl-4,15-dimethylidene-14-oxo-13,18-dioxatricyclo[10.3.2.1(5,8)]octadec-11-yl acetate|sinuladiterpene H
methyl 18-acetoxygrindelate|methyl-18-acetoxygrindeloate
7beta,14beta,15beta-trihydroxy-1alpha-acetoxy-7alpha,20-epoxy-ent-kaur-16-ene|enanderianin N
4alpha-acetoxy-3alpha-angeloyloxy-11-hydroxy-6,7-dehydroeudesman-8-one
13-acetoxy-7beta-angeloyloxy-3betaH-longipinan-1-one
rel-(7R,8S,1R,2S,4S,5R)-Delta8-2,4-dihydroxy-3,4,5-trimethoxy-1,2,3,4,5,6-hexahydro-7.O.2,8.1-neolignan
(4R,9S,13E,16E)-12-acetoxy-4-hydroxy-18-hydroperoxy-4,10-secospata-2,13(15),16-trien-10-one
(1R,3R,4S,7E,11E,13S,14R)-13-acetoxy-3,4-dihydroxycembra-7,11,15(17)-trien-16,14-olide|crassocolide I
2beta-ethoxy-6-O-(2-methylbutyryl)-2,3-dihydrohelenalin
17-Ac-8,12-Epoxy-16,17-dihydroxy-13-labden-15,16-olide
3beta,11beta,15beta-trihydroxy-6alpha-acetoxy-ent-kaur-16-ene|melissoidesin
3beta-acetoxy-8beta,14alpha-dihydroxy-3,15-abiatene-16,12-olide
7alpha,17beta-dihydroxy-15,17-oxidospongian-16-one 7-acetate|Aplyroseol 2
ent-1beta-acetoxy-12alpha,15alpha-dihydroxykaur-16-en-19-oic acid
7alpha,14beta,18-trihydroxy-20-acetoxy-ent-kaur-16-en-15-one|isolushinin H
21-Ac-(3alpha,5beta)-3,14,21-Trihydroxypregnan-20-one
21-Ac-(3alpha,5alpha,11beta)-3,11,21-Trihydroxypregnan-20-one
Di-Ac-5-[1-(2,2-Dimethylcyclopentylidene)ethyl]octahydro-4,4-dimethyl-1,3-isobenzofurandiol
rel-(1S,3S,4S,7R,8Z,11R,12S)-3-hydroxy-15-methylidene-4,8,12-trimethyl-14-oxo-13,18-dioxatricyclo[10.3.2.1(4,7)]octadec-8-en-11-yl acetate|sinuladiterpene C
10beta-acetoxy-2alpha,5alpha,9alpha-trihydroxy-3,11-cyclotax-4(2-)-en-13-one
rel-(1S,3S,4E,7E,9R,11R,12S)-3,9-dihydroxy-15-methylidene-4,8,12-trimethyl-14-oxo-13-oxabicyclo[10.3.2]heptadeca-4,7-dien-11-yl acetate|sinuladiterpene F
3-Ac-(3beta,5beta,14beta)-3,14,21-Trihydroxypregnan-20-one
4alpha-Acetoxy-3alpha-(2,3-epoxy-2-methylbutyryloxy)-eudesman-8-one|4alpha-Acetoxy-3alpha-<2,3-epoxy-2-methylbutyryloxy>-eudesman-8-one
3beta-acetoxy-abieta-8(14)-en-18-oic acid 9alpha,13alpha-endoperoxide
1alpha,3beta,11beta-trihydroxy-15beta-acetoxy-ent-kaur-16-en-6-one|nervonin J
6beta-acetoxy-12alpha,14beta-dihydroxycassa-(13)15-en-16,12-olide|caesalpinolide A
19-Ac-2,6,19-Trihydroxy-8,13-labdadien-15,16-olide
3-Ac-(3beta,5alpha,14beta,17alpha)-3,8,14-Trihydroxypregnan-20-one
15-acetoxy-12-(3-hydroxyisovaleryloxy)-cyperen-3-one|15-acetoxy-12-<3-hydroxyisovaleryloxy>-cyperen-3-one
2beta-methoxy-16-acetoxy-ent-labda-8(17),13Z-dien-15-oic acid
19-acetoxy-4alpha,18-epoxy-6alpha-hydroxyneoclerod-13-en-15,16-olide|ajugarin II|ajugarin-II
4beta,6alpha,8beta-trihydroxy-9alpha-p-hydroxybenzoyloxydaucane
(1R,3S,4S,14S,7E,11E)-18-acetoxy-3,4-dihydroxycembra-7,11,15(17)-trien-16,14-olide|durumolide F
3beta-acetoxy-6beta-[(2-methylbutanoyl)oxy]furanoeremophilan-10beta-ol
2-Acetoxy-5-methoxy-6-methyl-3-tridecyl-1,4-benzoquinone
10-Apo-Psi-carotin-10-saeure|apo-10-lycopenoic acid
3beta-angeloyloxy-4beta-acetoxy-7alpha-hydroxy-eudesman-11-en-8-one
3??-Hydroxy-7-acetoxy-4(18),13-clerodadien-15-oic acid methyl ester
3beta-acetoxy-7alpha,12alpha,14beta-trihydroxy-ent-kaur-16-en-15-one|pharicinin B
19-acetoxy-1beta,6beta-dihydroxy-7,16-dioxo-ent-abieta-15(17)-ene|eriocasin D
1beta-hydroxy-2beta-methylsenecioyloxy-8alpha-methoxyeremophil-7(11)-en-8beta(12)-olide
13-epi-preleosibirone A|3alpha-acetoxy-9alpha,13R;15,16-diepoxy-6beta-hydroxylabd-14-en-7-one
3alpha-acetoxy-9alpha,13S;15,16-diepoxy-7beta-hydroxylabd-14-en-6-one|isopreleosibirone A
(3S,5S,6R,9S)-megastigman-3,6,9-triol 3-O-beta-D-(-)-glucopyranoside|iso-dihydrodendranthemoside A|NSC# 742189
(2E,6E)-8-{[ (2E,6E)-8-Acetoxy-2,6-dimethylocta-2,6-dienoyl]oxy}-2,6-dimethylocta-2,6-dienoic acid
8beta-acetoxy-3beta-isobutyryloxyisocostic acid methyl ester
7alpha,12alpha,13alpha-trihydroxyabiet-8(14)-en-18-oic acid acetonide|aquilarabietic acid C
11alpha-hydroxyleukamenin E|7alpha,11alpha,14beta-trihydroxy-3beta-acetoxy-ent-kaur-16-en-15-one
5alpha-pregna-3beta-acetoxy-12beta,16beta-diol-20-one
4-oxo-2beta-ethoxy-6alpha-angeloyloxy-pesudoguaia-8beta,12-olide|minimolide B
methyl (4S)-3,4-seco-4,21-dihydroxy-4-methyl-20-oxo-5alpha-pregna-8-en-3-oate|nodulisporisteriod B
12alpha,14beta,18-trihydroxy-7alpha-acetoxy-ent-kaur-16-en-15-one|wikstroemioidin E
(2R,3R,20R)-2,20-dihydroxy-3,21-dimethoxypregn-5-en-7-one|heligenin A
methyl 15,17-epoxy-17alpha-acetoxy-ent-isocopalan-16-oate
(betaR,1R,4aS,5S,8aS)-1,4,4a,5,6,7,8,8a-octahydro-5-(methoxycarbonyl)-b,2,5,8a-tetramethyl-g,4-dioxonaphthalene-1-pentanoic acid methyl ester|13-epiloxocalyxin A
1alpha,6beta,14beta-trihydroxy-15beta-acetoxy-ent-kaur-16-en-7-one|hubeirubesin A
(1R,13S,12S,9S, 8R,5S,4R)-9-acetoxy-5,8:12,13-diepoxycembr-15(17)-en-16,4-olide
(17S)-16-oxo-2,3-secopregnan-2,3-dioic acid dimethyl ester
7alpha,12alpha,18-trihydroxy-14beta-acetoxy-ent-kaur-16-en-15-one|wikstroemioidin F
3beta-angeloyloxy-6beta,8alpha-dimethoxyeremophil-7(11)-en-12,8beta-olide
3-Ac-(3beta,5alpha,17alphaOH)-3,17,21-Trihydroxypregnan-20-one
12alpha-acetoxy-17beta-hydroxy-15,17-oxidospongian-16-one
6alpha,7beta,11beta-trihydroxy-3beta-acetoxy-ent-kaur-16-en-15-one|xindongnin F
12-O-acetylpseurata B|3alpha-7alpha,14beta-trihydroxy-12alpha-acetoxy-ent-kaur-16-en-15-one|pharicunin B
21-Ac-(3beta,5alpha,17alphaOH)-3,17,21-Trihydroxypregnan-20-one
19-acetoxy-3beta,6beta-dihydroxy-7,16-dioxo-ent-abieta-15(17)-ene|eriocasin C
13-Ac-(1S,3R,4R,7S,12S,13R,14R)-3,4-Epoxy-7,13-dihyroxy-8(19),15(17)-cembradien-16,14-olide
2-Methoxy-3-tridecyl-5-acetoxy-6-methyl-1,4-benzoquinone
8-[3-(2-dimethylaminoethyl)-5-hydroxy-1h-indol-4-yl]-1-methyl-2,3,8,8a-tetrahydro-1h-pyrrolo[2,3-b]indol-3a-ol
(12alpha)-2alpha-acetoxy-5alpha,9alpha,10beta-trihydroxy-3,11-cyclotax-4(20)-en-13-one|(12??)-2??-Acetoxy-5??,9??,10??-trihydroxy-3,11-cyclotax-4(20)-en-13-one
(7E,9S,11S,12R,13R)-11-(acetyloxy)-9-hydroxy-5,9-dimethyl-12-(1-methylethyl)-14-oxabicyclo[11.2.1]hexadeca-1(16),7-diene-3,15-dione|sacrophytonolide K
rel-(1S,3S,5S,8E,10R,12R,13S)-10-hydroxy-16-methylidene-5,9,13-trimethyl-15-oxo-4,14-dioxatricyclo[11.3.2.0(3,5)]octadec-8-en-12-yl acetate
rel-(7R,8S,1R,3R,4R,6S)-Delta8-4-hydroxy-3,4,3,6-tetramethoxy-8.1,7.O.6-neolignan
6-Ac 鈥樎?6alpha,17beta)-15,17-Epoxy-6,17-dihydroxy-16-spongianone|6alpha,17beta-dihydroxy-15,17-oxidospongian-16-one 6 acetate
4beta-acetoxy-3beta-angeloyloxy-7alpha,11-epoxyeudesman-8-one
3,16-Di-Ac-(3beta,5beta,16alpha,17beta)-Androstane-3,16,17-triol
6-alpha-malonyloxymanoyl oxide|6alpha-malonyloxymaloyl oxide
4alpha-angeloyloxy-5beta-hydroxy-13beta-methoxylupanine
2??-Hydroxy-7-acetoxy-3,13-clerodadien-15-oic acid methyl ester
2alpha-hydroxyajugarin V|6-Ac-(ent-2beta,4beta,6beta)-4,18-Epoxy-2,6-dihydroxy-13-cleroden-15,16-olide
7beta-acetoxy-15-hydroxylabda-8(17),13E-dien-19-oic acid methyl ester
3,17-Di-Ac-(3beta,5alpha,6alpha,17beta)-Androstane-3,6,17-triol
2-[[2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]propanoic acid
N-[(6-oxo-5-prop-2-enyl-1-cyclohexa-2,4-dienylidene)methyl]-2-[4-(phenylmethyl)-1-piperazinyl]acetohydrazide
Trospium
[C25H30NO3]+ (392.22255700000005)
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3030
(E)-3-(acetyloxymethyl)-5-(2-formyl-4-hydroxy-5,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)pent-2-enoic acid
C22H32O6_(1S,2R,4aR,8aR)-1-Acetoxy-7-isopropylidene-1,4a-dimethyl-6-oxodecahydro-2-naphthalenyl 2,3-dimethyl-2-oxiranecarboxylate
C22H32O6_1-Naphthalenecarboxylic acid, 1,2,3,4,4a,5,8,8a-octahydro-1,4a,6-trimethyl-5-[(2,3,5-trihydroxy-4-methylene-7-oxabicyclo[4.1.0]hept-1-yl)methyl]
C19H36O8_[5-Hydroxy-2-(3-hydroxybutyl)-3,3-dimethylcyclohexyl]methyl beta-D-glucopyranoside
Dextromoramide
C25H32N2O2 (392.24636519999996)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
(E)-3-(acetyloxymethyl)-5-(2-formyl-4-hydroxy-5,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)pent-2-enoic acid [IIN-based on: CCMSLIB00000845030]
(E)-3-(acetyloxymethyl)-5-(2-formyl-4-hydroxy-5,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)pent-2-enoic acid [IIN-based: Match]
Ala Phe Gly Val
Ala Phe Val Gly
Ala Gly Phe Val
Ala Gly Val Phe
Ala Val Phe Gly
Ala Val Gly Phe
Phe Ala Gly Val
Phe Ala Val Gly
Phe Gly Ala Val
Phe Gly Gly Ile
Phe Gly Gly Leu
Phe Gly Ile Gly
Phe Gly Leu Gly
Phe Gly Val Ala
Phe Ile Gly Gly
Phe Leu Gly Gly
Phe Val Ala Gly
Phe Val Gly Ala
Gly Ala Phe Val
Gly Ala Val Phe
Gly Phe Ala Val
Gly Phe Gly Ile
Gly Phe Gly Leu
Gly Phe Ile Gly
Gly Phe Leu Gly
Gly Phe Val Ala
Gly Gly Phe Ile
Gly Gly Phe Leu
Gly Gly Ile Phe
Gly Gly Leu Phe
Gly Ile Phe Gly
Gly Ile Gly Phe
Gly Leu Phe Gly
Gly Leu Gly Phe
Gly Val Ala Phe
Gly Val Phe Ala
Ile Phe Gly Gly
Ile Gly Phe Gly
Ile Gly Gly Phe
Leu Phe Gly Gly
Leu Gly Phe Gly
Leu Gly Gly Phe
Val Ala Phe Gly
Val Ala Gly Phe
Val Phe Ala Gly
Val Phe Gly Ala
Val Gly Ala Phe
Val Gly Phe Ala
13,14-dihydro-16,16-difluoro Prostaglandin F2&alpha
C20H34F2O5 (392.23741780000006)
13,14-dihydro-16,16-difluoro Prostaglandin E1
C20H34F2O5 (392.23741780000006)
PAC-1
C274 - Antineoplastic Agent > C129839 - Apoptotic Pathway-targeting Antineoplastic Agent
Trospium
C25H30NO3+ (392.22255700000005)
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
Indacaterol
C24H28N2O3 (392.20998180000004)
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research[1][2].
VX-770
C24H28N2O3 (392.20998180000004)
D049990 - Membrane Transport Modulators > D065101 - Chloride Channel Agonists C87006 - Pharmacological Chaperone R - Respiratory system
Methyl (9Z)-6'-oxo-6,5'-diapo-6-carotenoate
Dihydrofukinolide
A sesquiterpene lactone that is (3R,3aR)-decahydrospiro[furan-3,2-indene] carrying an oxo, methylene, acetoxy, [(2S)-2-methylbutanoyl]oxy, methyl and methyl groups at positions 2, 4, 3, 4, 7 and 7a, respectively.
apo-3-Zeaxanthinal
FA 22:6;O4
Penicildione D
5-((3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaen-1-yl)resorcinol
1,1-(9-(3-(DIMETHYLAMINO)PROPYL)-9H-CARBAZOLE-3,6-DIYL)BIS(2-METHYLPROPAN-1-ONE)
C25H32N2O2 (392.24636519999996)
Racemoramide
C25H32N2O2 (392.24636519999996)
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
tert-butyl 1-benzylspiro[1,3-dihydroisoquinoline-4,4-piperidine ]-2-carboxylate
C25H32N2O2 (392.24636519999996)
Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclohexyl-N-(3-methoxyphenyl)- (9CI)
methyl (2s)-2-[[(2s)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]-3-phenylpropanoate
1,4-Cyclohexanedimethanol bis(3,4-epoxycyclohexanecarboxylate)
Toreforant
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C78284 - Agent Affecting Integumentary System > C29708 - Anti-psoriatic Agent Toreforant is a potent and selective histamine H4 receptor (H4R) antagonist, with a Ki at the human receptor of 8.4 nM.
Methyl 3-(tert-butyldimethylsilyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
2-[2-[4-(diethylamino)phenyl]vinyl]-1,3,3-trimethyl-3H-indolium acetate
C25H32N2O2 (392.24636519999996)
20,22-Dihydrodigoxigenin
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
(E)-N-(3-allyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide
13,14-dihydro-16,16-difluoro Prostaglandin F2alpha
C20H34F2O5 (392.23741780000006)
1,1,2,2,5,5,6,6-Octaethyl-3,4,7,8-tetradehydro-1,2,5,6-tetrahydro-1,2,5,6-tetrasilocine
C20H40Si4 (392.22069600000003)
Ivacaftor
C24H28N2O3 (392.20998180000004)
D049990 - Membrane Transport Modulators > D065101 - Chloride Channel Agonists C87006 - Pharmacological Chaperone R - Respiratory system
(E)-3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-4-hydroxybut-2-enoic acid
methyl (E)-7-[2-[(E)-4-ethenyl-4-hydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoate
(2E,6E)-8-{[(2E,6E)-8-acetoxy-2,6-dimethylocta-2,6-dienoyl]oxy}-2,6-dimethylocta-2,6-dienoic acid
A natural product found in Anarrhinum orientale.
[(1R,2R,4R,8S,9R,10S,13R,16R)-2,8,16-trihydroxy-5,5-dimethyl-14-methylidene-15-oxo-9-tetracyclo[11.2.1.01,10.04,9]hexadecanyl]methyl acetate
3-(1H-indol-3-yl)propanoic acid [2-[tert-butyl-(phenylmethyl)amino]-2-oxoethyl] ester
C24H28N2O3 (392.20998180000004)
N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycinate
C22H34NO5- (392.24368540000006)
A monocarboxylic acid anion that is the conjugate base of N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycine, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycinate
C22H34NO5- (392.24368540000006)
A monocarboxylic acid anion that is the conjugate base of N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycine, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7S,8E,10Z,13Z,15E,17S,19Z)-7,17-bis(hydroperoxy)docosa-4,8,10,13,15,19-hexaenoic acid
(4Z,7Z,11Z,13Z,15E,17S,19Z)-10,17-bis(hydroperoxy)docosa-4,7,11,13,15,19-hexaenoic acid
(4Z,7S,8E,10Z,12E,14S,16Z,19Z)-7,14-bis(hydroperoxy)docosa-4,8,10,12,16,19-hexaenoic acid
2-oxo-3-[(2E,6E)-farnesyl]-6-(pyridin-3-yl)-2H-pyran-4-olate
C25H30NO3- (392.22255700000005)
Leu-Phe-Asn
A tripeptide composed of L-leucine, L-phenylalanine and L-asparagine joined in sequence by peptide linkages.
2-(4-Methylphenoxy)-1-[4-(4-phenylcyclohexyl)piperazin-1-yl]ethanone
C25H32N2O2 (392.24636519999996)
1-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea
1-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea
N-[3-(dimethylamino)propyl]-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[[(2R,3S,4S)-1-benzoyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-methylcyclobutanecarboxamide
C24H28N2O3 (392.20998180000004)
[(1S,5R)-7-[4-(3-methoxyphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-(4-oxanyl)methanone
C24H28N2O3 (392.20998180000004)
1-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea
1-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea
(E)-3-(acetyloxymethyl)-5-(2-formyl-4-hydroxy-5,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)pent-2-enoic acid
1-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea
N-[3-(dimethylamino)propyl]-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[3-(dimethylamino)propyl]-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[[(2S,3R,4R)-1-benzoyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-N-methylcyclobutanecarboxamide
C24H28N2O3 (392.20998180000004)
[(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-1-methylsulfonyl-4-[(propan-2-ylamino)methyl]-2-azetidinyl]methanol
C21H32N2O3S (392.21335220000003)
(1S,2S,3E,7S,8R,11S,12Z)-7-Acetoxy-8,11-dihydroxycembra-3,12,15-trien-17,2-olide
(1-acetyloxy-3-hydroxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(1-butanoyloxy-3-hydroxypropan-2-yl) (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
2-[Carboxy-(2-hydroxy-3-nonanoyloxypropoxy)methoxy]ethyl-trimethylazanium
Arterolane
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides
AMN082 free base
AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects[1][2].
1-Palmitylglycerone 3-phosphate(2-)
A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-palmitylglycerone 3-phosphate; major species at pH 7.3.
Epoxypholamin C, (rel)-
A natural product found in Paraconiothyrium species.
(7S,17S)-bis(hydroperoxy)-(4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid
A docosanoid that is (4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroperoxy substituents at the 7S- and 17S-positions.
(Z)-7-(5-((1E,3E,6Z,9Z)-dodeca-1,3,6,9-tetraen-1-yl)-1,2-dioxolan-3-yl)-7-hydroperoxyhept-4-enoic acid
(4Z,7Z,11Z,13Z,15E,17S,19Z)-10,17-bis(hydroperoxy)docosahexaenoic acid
A docosanoid that is (4Z,7Z,11Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroperoxy substituents at positions 10 and 17.
(7S,14S)-bis(hydroperoxy)-(4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid
A docosanoid that is (4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid carrying two hydroperoxy substituents at the 7S- and 14S-positions.
DG(20:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Gboxin
C22H33ClN2O2 (392.22304280000003)
Gboxin is an oxidative phosphorylation (OXPHOS) inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase. Antitumour activity[1].